Gilead Sciences (GILD) Tops Q2 EPS by 44c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Gilead Sciences' (GILD) Price Target Bumped to $135 at Deutsche Bank
July 29, 2015 10:13 AM EDTDeutsche Bank maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) and raised its price target to $135.00 (from $125.00). Analyst Robyn Karnauskas characterized Q2 results as "solid" and said HCV discounts don't look bad.
"We are lowering our US HCV revenues while increasing OUS numbers & model WW revs at $18.5B vs.... More
Gilead Sciences (GILD) PT Raised to $134 at Piper Jaffray on Another 'Beat and Raise'
July 29, 2015 9:10 AM EDTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and boosted his price target on Gilead Sciences (NASDAQ: GILD) to $134.00 (from $131.00) following another 'beat and raise'.
Schimmer commented, "GILD hosted its 2Q earnings call after the close and again easily beat consensus product... More
Gilead Sciences (GILD) PT Lifted to $135 at Baird on Strong Earnings Beat
July 29, 2015 6:58 AM EDTBaird analyst Brian Skorney lifted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $135.00 (from $126.00) following earnings beat.
Skorney commented, "Gilead handily beat expectations, across the board, and raised revenue guidance yet again. Interestingly, nothing in Hep C declined... More
Gilead Sciences (GILD) PT Raised to $120 at Oppenheimer on Solid Q2 Beat
July 29, 2015 6:28 AM EDTOppenheimer analyst Wendy Lam reiterated an Outperform rating and boosted her price target on Gilead Sciences (NASDAQ: GILD) to $120.00 (from $86.00) following solid the Q2 beat.
Lam commented, "GILD reported a healthy 2Q15 EPS and product revenues beat ($3.15/$8.13B vs. $2.71/$7.60B consensus) underpinned by... More
Gilead Sciences (GILD) Declares $0.43 Quarterly Dividend; 1.5% Yield
July 28, 2015 5:18 PM EDTGilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.43 per share, or $1.72 annualized.
The dividend will be payable on September 29, 2015, to stockholders of record on September 16, 2015, with an ex-dividend date of September 14, 2015.
The annual yield on the dividend is 1.5... More

